AK112 (Not yet branded)

Description

AK112 is a bispecific antibody designed to simultaneously target two immune checkpoint pathways in colorectal cancer treatment. This immunotherapy agent is being developed specifically for patients with microsatellite stable (MSS) colorectal cancer, a population that typically shows poor response to conventional checkpoint inhibitors. AK112 is utilized in combination with chemotherapy for first-line treatment of metastatic colorectal cancer and as part of neoadjuvant therapy regimens for locally advanced rectal cancer.

Mechanism of Action

AK112 functions as a bispecific antibody that simultaneously blocks two distinct immune checkpoint pathways, enhancing T-cell activation and anti-tumor immune responses. By targeting multiple inhibitory signals simultaneously, this approach aims to overcome the immune-suppressive tumor microenvironment characteristic of MSS colorectal cancers, which are typically resistant to single-agent checkpoint inhibition.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials